If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.00
Bid: 16.50
Ask: 17.50
Change: -0.50 (-2.86%)
Spread: 1.00 (6.061%)
Open: 17.50
High: 17.50
Low: 17.00
Prev. Close: 17.50
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Dianomi swings to loss; Epwin revenue up

Wed, 20th Sep 2023 14:27

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Epwin Group PLC - Solihull, England-based building products manufacturer - Revenue in six months to June 30 up 1.1% to GBP180.0 million from GBP178.0 million. Pretax profit flat at GBP7.9 million. Interim dividend per share rises 5.3% to 2.0 pence from 1.9p a year prior. "Q3 trading to date has been encouraging with profitability ahead of 2022," Epwin adds. It expects to report annual results in line with market expectations. Underlying operating profit expectations stand at GBP24.0 million, which would represent a 12% rise from GBP21.5 million in 2022.

----------

Dianomi PLC - London-based digital advertising platform - Revenue in half-year ended June 30 drops 18% to GBP14.8 million from GBP18.0 million, amid "decline in traffic volumes across the group's direct publisher inventory". Swings to pretax loss of GBP2.1 million from profit of GBP897,000 a year earlier. "We are mindful of an environment that continues to be challenging and the need to adapt. The group's operational cost base has been streamlined and optimised following the restructuring of the group's global management and sales teams, resulting in an annualised cost reduction of GBP1 million. However, in spite of a difficult backdrop, I am pleased to report that Dianomi continues to attract new clients and now counts all 10 of the top 10 US asset managers as clients," Chief Executive Rupert Hodson says. Dianomi expects a profitable second-half. In addition, the firm explained it has agreed a contract amendment with "one of its largest and longest standing publisher partners". While bullish that the amendment is good news in the long-term, Dianomi noted the arrangement hurt its adjusted earnings before, interest, tax, depreciation and amortisation for the six months of 2023. "There will be a short-term impact on cash of GBP500,000 in the current financial year which will unwind during 2024," the firm says. Dianomi says minimum traffic levels were not met, meaning it was overpaid by the publisher to tune of USD1 million. Dianomi adds: "Following discussions, the company and the publisher have entered into an amendment to the agreement whereby Dianomi has agreed not to recoup the overpayment, in return for which the publisher will provide Dianomi with an enhanced revenue share as from 1 July 2023 and, in addition to its existing permanent ad units, will provide Dianomi with additional premium ad inventory, including a new in-article unit."

----------

Ten Entertainment Group PLC - ten-pin bowling operator - Total sales in half-year ended July 2 improve 3.3% on-year to GBP65.3 million from GBP63.2 million a year earlier. Pretax profit, however, falls by a quarter to GBP15.8 million from GBP21.0 million. The prior year's bottom line got a GBP4.4 million boost from a claim for reduced rate of VAT on bowling. Ten Entertainment adds: "An ongoing focus on refurbishment, customer service and digital communications gives us confidence that we can continue to deliver like-for-like sales growth from the existing estate through addition of new activities and focus on the core entertainment experience. Cost inflation remains manageable, and we expect a slightly lower than the UK headline rate as a function of our long-term supplier strategy." The firm adds year-to-date like-for-like sales are 4.7% higher.

----------

DP Aircraft I Ltd - Guernsey-based aircraft leasing company - Lease rental in six months to June 30 falls 43% to USD4.3 million from USD7.6 million a year earlier. DP Aircraft swings to a pretax loss of USD4.1 million from profit of USD3.0 million. "There has been a continued improvement in the global aviation market following the challenges resulting from the effects of the Covid-19 pandemic. Recent sentiment on airline and related stocks has been more optimistic. The Ukraine war has not had as significant an impact on the industry as expected. With Covid-19 restrictions in China being lifted there is cause for some optimism in tourism numbers from that market in Thailand going forward," DP Aircraft says.

----------

Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology company focused on preventing life-threatening infections - Reports licence fee income of GBP831,552 in first half ended June 30, against none a year earlier. Pretax loss narrows to GBP3.1 million from GBP3.8 million. CEO Chris Tovey says: "The partnering of NTCD-M3 and the associated fundraising during the period demonstrate our ability to generate significant value from our assets, and have positioned the company for success as we advance the Phase 3 development programme for M3 and intensify our partnering activities for our lead asset, XF-73 nasal. The company is now funded through to Q1 2025, allowing us to deliver our planned activities."

----------

Ethernity Networks Ltd - supplier of data processing semiconductor technology for networking appliances - Revenue in first half ended June 30 surges 98% to USD1.4 million from USD704,853. Pretax loss, however, widens to USD3.6 million from USD3.5 million. Reports financing income of just GBP322,814, down from GBP1.2 million a year earlier. Ethernity adds: "The company is targeting the achievement of positive cash flow generation from operations during the second half of 2023 by continuing to fulfil customers' orders and from anticipated revenue from new contracts, in combination with a reduction in expenses."

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
17 Dec 2019 16:06

Destiny Pharma Says New Guidelines Prove Lead Product Marketability

Destiny Pharma Says New Guidelines Prove Lead Product Marketability

Read more
2 Dec 2019 15:57

Destiny Pharma Appoints Former Polyphor Medical Chief To Board

Destiny Pharma Appoints Former Polyphor Medical Chief To Board

Read more
16 Oct 2019 14:48

Destiny Pharma pleased with latest XF-73 results at it proceeds with next phase

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma reported on the publication of results from a positive phase 1 clinical study in 60 healthy United States volunteers using a nasal gel formulation of its lead drug, XF-73 (exeporfinium chloride), on Wednesday.

Read more
16 Oct 2019 11:36

Destiny Pharma's XF-73 Associated With Reduced Staphylococcus Aureus

Destiny Pharma's XF-73 Associated With Reduced Staphylococcus Aureus

Read more
23 Sep 2019 16:09

Destiny Pharma Says Non-Executive Joe Eagle Steps Down From Board

Destiny Pharma Says Non-Executive Joe Eagle Steps Down From Board

Read more
23 Sep 2019 12:12

Destiny Pharma Interim Loss Narrows On Smaller Share Option Charge

Destiny Pharma Interim Loss Narrows On Smaller Share Option Charge

Read more
10 Sep 2019 14:16

Destiny Pharma Collaboration With University Of Sheffield Wins Funding

(Alliance News) - Destiny Pharma PLC on Tuesday said it has been awarded a grant along with the University of Sheffield for their research collaboration on drug-resistant infections.Shares

Read more
9 Apr 2019 11:17

Destiny Pharma Annual Loss Doubles On Higher Costs, Confident Outlook

LONDON (Alliance News) - Destiny Pharma PLC on Tuesday reported a significantly widened annual loss as expenses surged in the run-up to the development of its lead candidate.For 2018, the a

Read more
9 Apr 2019 09:32

Destiny Pharma 'well funded' despite wider loss

(Sharecast News) - Destiny Pharma on Tuesday reported a wider annual loss as it increased research and development costs, although the company is "well funded" through to the second half of next year.

Read more
2 Apr 2019 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 3 April AAFull Year ResultsCMC MarketsTrading GroupTrading Year Year 4

Read more
27 Mar 2019 11:53

Destiny Pharma, MedPharm To Develop New XF-Platform Drug Formulations

LONDON (Alliance News) - Destiny Pharma PLC on Wednesday said it has partnered with MedPharm to develop new formulations of its XF-platform compounds.MedPharm is a contract provider of and

Read more
28 Jan 2019 11:46

Destiny Pharma Gets Positive Results From Second Phase Trial Of XF-73

LONDON (Alliance News) - Destiny Pharma PLC on Monday reported positive results in a second phase 1 clinical study examining the anti-irritation features of its XF-73 nasal gel.The study, a

Read more
28 Jan 2019 10:39

Destiny Pharma sees success in latest trial of XF-73 nasal gel

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma announced positive data and the non-irritant classification for its XF-73 nasal gel on Monday.

Read more
25 Jan 2019 10:58

Destiny Pharma leaps on £1.6m grant and UK-China collaboration

(Sharecast News) - Destiny Pharma jumped on Friday after being awarded funding of up to £1.6m from a collaboration established under the UK-China AMR grant fund.

Read more
25 Jan 2019 09:53

Destiny Pharma Gets Funding For Antimicrobial Resistance Research

LONDON (Alliance News) - Destiny Pharma PLC said Friday that it has secured a GBP1.6 million grant for examining novel drugs to prevent, control and eradicate life threatening bacteria or without

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.